Ireland: Biosynth Carbosynth expands IVD offering with acquisition of Aalto Bio Reagents

Urs Spitz (left) – CEO and President, Biosynth Carbosynth and Philip Noone (right) – CEO, Aalto Bio Reagents

KKR-backed Biosynth Carbosynth, a materials supplier to the life science industry, has acquired Ireland-based Aalto Bio Reagents is a global provider of proteins, antigens, HIV antibodies and disease state human plasma to the in-vitro diagnostic (IVD) industry. Financial terms were not disclosed. The acquisition broadens Switzerland-based Biosynth’s capabilities and offering to the IVD industry. Aalto’s product…

You must be a HMI Subscriber to view this content.

Subscribe Now »